BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).

被引：6
|
作者：
El-Rayes, Bassel F.
Richards, Donald A.
Cohn, Allen Lee
Richey, Stephen Lane
Feinstein, Trevor
Kundranda, Madappa N.
El-Khoueiry, Anthony B.
Melear, Jason M.
Braiteh, Fadi S.
Hitron, Matthew
Ortuzar, Waldo Feliu
Khan, Waheed
Xu, Bo
Li, Wei
Li, Youzhi
Li, C. J.
机构：
[1] Winship Canc Inst, Atlanta, GA USA
[2] Texas Oncol, Tyler, TX USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] US Oncol Network, McKesson Specialty Hlth, Texas Oncol, Ft Worth, TX USA
[5] Piedmont Canc Inst, Fayetteville, GA USA
[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[8] Texas Oncol, Round Rock, TX USA
[9] US Oncol Network, McKesson Specialty Hlth, The Woodlands, TX USA
[10] Boston Biomed Inc, Cambridge, MA USA
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
[12] Boston Biomed Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：5
相关论文
共 44 条
  • [21] Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
    Hubbard, Joleen Marie
    O'Neil, Bert H.
    Jonker, Derek J.
    Halfdanarson, Thorvardur Ragnar
    Starodub, Alexander
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    O'Neil, Bert H.
    Bendell, Johanna C.
    Modiano, Manuel R.
    Machiels, Jean-Pascal H.
    Versola, Melissa Jo
    Hodge, Jeff Paul
    Sawarna, Karen
    Tse, Nielson
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [23] CanStem303C trial: A phase III study of BBI-608 (napabucasin) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC)
    Grothey, A.
    Tebbutt, N.
    Van Cutsem, E.
    Taieb, J.
    Falcone, A.
    Yoshino, T.
    Cervantes, A.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).
    Grothey, Axel
    Shah, Manish A.
    Yoshino, Takayuki
    Van Cutsem, Eric
    Taieb, Julien
    Xu, Ruihua
    Tebbutt, Niall C.
    Falcone, Alfredo
    Cervantes, Andres
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Sarker, Debashis
    Sodergren, Mikael
    Plummer, Elizabeth Ruth
    Basu, Bristi
    Meyer, Tim
    Huang, Kai-Wen
    Evans, T. R. Jeffry
    Spalding, Duncan
    Ma, Yuk Ting
    Palmer, Daniel H.
    Chee, Cheng Ean
    Pinato, David James
    Reebye, Vikash
    McVeigh, Daniel
    Raulf, Nina
    Vasara, Jenni
    Andrikakou, Pinelopi
    Habib, Robert
    Blakey, David
    Habib, Nagy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy
    Ciombor, Kristen Keon
    Edenfield, William Jeffery
    Hubbard, Joleen Marie
    O'Dwyer, Peter J.
    Becerra, Carlos
    Larson, Tim
    Spira, Alexander I.
    Grothey, Axel
    Manoharan, Divya
    Li, Wei
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Lim, Ho Yeong
    Oh, Do-Youn
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Beckman, Robert A.
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Shahda, Safi
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Starodub, Alexander
    Hanna, Wahid Tewfik
    Borodyansky, Laura
    Oh, Cindy
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC) (vol 27, pg 2210, 2016)
    Tai, W. M.
    Yong, W. P.
    Lim, C.
    Low, L. S.
    Tham, C. K.
    Koh, T. S.
    Ng, Q. S.
    Wang, W. W.
    Wang, L. Z.
    Hartono, S.
    Thng, C. H.
    Huynh, H.
    Lim, K. T.
    Toh, H. C.
    Goh, B. C.
    Choo, S. P.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 526 - 526
  • [30] Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Lee, Ann Sing
    Zee, Benny C. Y.
    Cheung, Foon Yiu
    Kwong, Philip
    Cheng, Ashley Chi Kin
    Lai, Maria
    Kwok, Chloe
    Chong, Marc
    Jolivet, Jacques
    Chiang, C. L.
    Leung, K. C.
    Siu, Steven
    Lee, Conrad
    Tung, Stewart Yuk
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345